Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-A11:01 and HLA-C03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups.

HLA - 1 Apr 2026

Lv Yuanzhi, Chen Kangzhi, Luo Mengchuan, Ouyang Yuzhen, Li Kailin, Luo Zhaohui, Yang Huan

Abstract excerpt

Tacrolimus (TAC) is recommended for the patients with drug tolerance or respond poorly to other conventional immunosuppressants in myasthenia gravis (MG), but its effectiveness is influenced by dose and genetic polymorphism. Studies suggest that HLA polymorphisms are significantly associated with susceptibility to MG, but the relationship between HLA and TAC efficacy in MG has not been explored. In this paper, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HLA-A Antigens
Share to HLA-C Antigens
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Docking Simulation

Share to Myasthenia Gravis

Share to Protein Binding

Share to Tacrolimus

Share to Tacrolimus Binding Proteins

Source

Identifiers

PMID: 41925081
DOI: 10.1111/tan.70697

Genes

FKBP1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-A*11:01 and HLA-C*03 Binding to FKBP1A Influences the Efficacy of Tacrolimus in Myasthenia Gravis Subgroups.PMID 41925081Read ↗

Tacrolimus personalized therapy based on CYP3A5 genotype in Chinese patients with idiopathic inflammatory myopathies.Semantic proximity Read ↗

Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.Semantic proximity Read ↗

Correlation Between the Prevalence of Myasthenia Gravis and the Frequency of Class II Human Leucocyte Antigen Alleles in Various Geographical Locations Around the WorldSemantic proximity Read ↗

[Correlation study between Chinese myasthenia gravis patients from Guangdong province and the polymorphism of HLA immunogene].Semantic proximity Read ↗

Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.Semantic proximity Read ↗

Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.Semantic proximity Read ↗

Population Pharmacokinetics and Dose Optimization of Tacrolimus in Chinese Adult Patients with Myasthenia GravisSemantic proximity Read ↗

Clinical characteristics and outcome of treatment-refractory myasthenia gravis -a retrospective studySemantic proximity Read ↗

The associations of HLA-DRB1 gene polymorphisms with late-onset myasthenia gravis: a meta-analysis.Semantic proximity Read ↗

HLA genotypes in Turkish patients with myasthenia gravis: comparison with multiple sclerosis patients on the basis of clinical subtypes and demographic features.Semantic proximity Read ↗

The investigation of killer-cell immunoglobulin-like receptors (KIRs) and their HLA ligands in Iranian patients with myasthenia gravis.Semantic proximity Read ↗

Association of HLA Class II Alleles with Disease Severity and Treatment Response in Iranian Patients with Myasthenia GravisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.